Related Experiment Video
Updated: Jul 18, 2026
02:47
Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
How useful are beta-blockers in cardiovascular disease?
Sripal Bangalore1, Sanobar Parkar, Franz H Messerli
1Department of Medicine, Division of Cardiology, St. Luke's-Roosevelt Hospital, Columbia University, New York, New York 10019, USA.
Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
|December 13, 2006
Summary
Beta-blockers may increase stroke risk in hypertension patients, questioning their first-line use. However, they remain vital for heart failure and post-myocardial infarction treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Recent studies link beta-blockers in hypertension to increased cardiovascular events, particularly stroke.
- This has prompted debate regarding the continued use of beta-blockers.
Purpose of the Study:
- To critically evaluate the efficacy and risk-benefit profile of beta-blockers in cardiovascular diseases.
- To assess their utility in hypertension versus other cardiac conditions.
Main Methods:
- Comprehensive review of existing scientific literature and clinical evidence.
- Analysis of beta-blocker effectiveness for hypertension, heart failure, angina, myocardial infarction, and arrhythmias.
Main Results:
- Limited evidence supports beta-blockers as monotherapy or first-line treatment for uncomplicated hypertension.
- The risk-benefit ratio is unfavorable for hypertension due to stroke risk and adverse effects.
- Beta-blockers demonstrate high efficacy in treating heart failure, arrhythmias, and post-myocardial infarction.
Conclusions:
- Guideline committees should reassess the recommendation of beta-blockers for uncomplicated hypertension.
- Beta-blockers remain essential and effective for specific cardiovascular indications beyond hypertension.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...